Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.
Zentalis Pharmaceuticals has raised $235.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2023.
Zentalis Pharmaceuticals's investors include Pfizer, Perceptive Advisors, Redmile Group, Farallon Capital Management, Viking Global Investors.
Zentalis Pharmaceuticals is headquartered in New York, United States.
Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.
Zentalis Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Zentalis Pharmaceuticals — Funding & Investors." VCBacked, June 15, 2023, https://www.vcbacked.co/company/zentalis-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2023). Zentalis Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/zentalis-pharmaceuticals
{{cite web |title=Zentalis Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/zentalis-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated